docruДоктор.РуTitle1727-23782713-2994ООО "ГК "РУСМЕДИКАЛ"10.31550/1727-2378-2022-21-4-36-42docru-85Research ArticleНЕВРОЛОГИЯNEUROLOGYЛечение пациентов со скелетно-мышечным болевым синдромом в период пандемии COVID-19Management of Patients with Musculoskeletal Pain Syndrome during COVID-19 PandemicКамчатновП. РKamchatnovP. R.

Камчатнов Павел Рудольфович — д. м. н., профессор кафедры неврологии, нейрохирургии и медицинской генетики лечебного факультета

121996, г. Москва, ул. Островитянова, д. 1

1 Ostrovityanov Str., Moscow, 121996

pavkam7@gmail.comhttps://orcid.org/0000-0003-4506-8095ЧугуновА. В.ChugunovA. V.

Чугунов Александр Вильмирович — д. м. н., профессор кафедры неврологии, нейрохирургии и медицинской генетики лечебного факультета

121996, г. Москва, ул. Островитянова, д. 1

1 Ostrovityanov Str., Moscow, 121996

pavkam7@gmail.comФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства здравоохранения Российской ФедерацииРоссияN.I. Pirogov Russian National Research Medical Universityof the Ministry of Health of the Russian FederationRussian Federation202215022025214НЕВРОЛОГИЯ. ПСИХИАТРИЯ3642Copyright © Камчатнов П.Р., Чугунов А.В., 20252025Камчатнов П.Р., Чугунов А.В.Kamchatnov P.R., Chugunov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://docru.elpub.ru/jour/article/view/85Цель обзора

Цель обзора: рассмотреть эффективность и безопасность использования нестероидных противовоспалительных препаратов (НПВП) у пациентов с поясничной болью (ПБ), в том числе при COVID-19.

Основные положения

Основные положения. Скелетно-мышечные болевые синдромы, в частности ПБ, широко распространены, негативно влияют на качество жизни больных, приводят к существенным расходам на лечебные мероприятия. У многих пациентов, перенесших COVID-19, ПБ появляется или усиливается. Трудности ведения таких больных обусловлены поражением различных органов и систем организма, необходимостью принимать одновременно большое количество лекарственных препаратов, что увеличивает риск их взаимодействия. В обзоре приведены сведения об эффективности и безопасности применения нимесулида у больных с ПБ. Рассматриваются данные об использовании НПВП у больных COVID-19. Анализируются положительные эффекты нимесулида и возможные риски при его назначении.

Заключение

Заключение. Ведение больных с ПБ в условиях пандемии COVID-19 требует тщательного выбора оптимальной терапии с учетом имеющейся коморбидности и высокого риска лекарственных взаимодействий. Нимесулид является эффективным лекарственным препаратом, обладающим хорошим профилем безопасности и переносимости. Его целесообразно применять при лечении пациентов с ПБ, в том числе перенесших COVID-19. Безопасность проводимой терапии может быть обеспечена тщательным учетом имеющейся сопутствующей патологии и факторов риска развития потенциальных осложнений лечения.

Objective of the Review

Objective of the Review: To discuss the efficiency and safety of the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with low back pain (LBP), also during COVID-19 pandemic.

Key Points

Key Points. Musculoskeletal pain syndromes, including LBP, are common; they affect the quality of patients’ life and result in huge medical bills. In a lot of post-COVID-19 patients, LBP appears for the first time or gets worse. Challenges in the management of such patients are caused by involvement of multiple organs and body systems, the need in taking numerous medications at once, which increases the risk of drug interaction. This overview describes the efficiency and safety of nimesulide in patients with low back pain. The use of NSAIDs in patients with COVID-19 is discussed. Beneficial effects and possible risks of nimesulide are analysed.

Conclusion

Conclusion. Management of patients with LBP during the COVID-19 pandemic requires thorough selection of an optimal therapy taking into account comorbidities and a high risk of drug-drug interactions. Nimesulide is a potent medication with a favourable safety and tolerability profile. It is advisable to use nimesulide in the management of patients with low back pain, including COVID-19 survivors. Safety of the therapy can be ensured by thorough drug selection taking into account comorbidities and risks of complications.

скелетно-мышечные болевые синдромыпоясничная больCOVID-19постковидный синдромнестероидные противовоспалительные препаратынимесулидлечениепобочные эффектыmusculoskeletal pain syndromeslow back painCOVID-19post-COVID syndromenonsteroidal anti-inflammatory drugsnimesulidemanagementside effectsReferencesКаратеев А.Е., Лила А.М., Дыдыкина И.С., Камчатнов П.Р. и др. Персонификация применения нестероидных противовоспалительных препаратов при скелетномышечных заболеваниях. Резолюция по результатам совещания экспертов от 13 декабря 2017 года. Медицинский совет. 2018; 18: 76–84. DOI: 10.21518/2079-701X-2018-18-76-84Karateev A.E., Lila A.M., Dydykina I.S., Kamchatnov P.R. et al. Personalization of the use of non-steroidal anti-inflammatory drugs for musculoskeletal diseases. Resolution on the results of the Meeting of Experts of December 13, 2017. Medical Council. 2018; 18: 76–84. (in Russian) DOI: 10.21518/2079-701X-2018-18-76-84Парфёнов В.А., Яхно Н.Н., Кукушкин М.Л., Чурюканов М.В. и др. Острая неспецифическая (скелетно-мышечная) поясничная боль. Рекомендации Российского общества по изучению боли (РОИБ). Неврология, нейропсихиатрия, психосоматика. 2018; 10(2): 4–11. DOI: 10.14412/2074-2711-2018-2-4-11[Parfenov V.A., Yakhno N.N., Kukushkin M.L., Churyukanov M.V. et al. Acute nonspecific (musculoskeletal) low back pain Guidelines of the Russian Society for the Study of Pain (RSSP). Neurology, Neuropsychiatry, Psychosomatics. 2018; 10(2): 4–11. (in Russiam). DOI: 10.14412/2074-2711-2018-2-4-11Manchikanti L., Pampati V., Jha S.S., Sanapati M.R. et al. The impact of COVID-19 on interventional pain management practices is significant and long-lasting: an interventional pain management physician survey. Pain Physician. 2022; 25(2): 131–44.Manchikanti L., Pampati V., Jha S.S., Sanapati M.R. et al. The impact of COVID-19 on interventional pain management practices is significant and long-lasting: an interventional pain management physician survey. Pain Physician. 2022; 25(2): 131–44.Gharaei H., Diwan S. COVID-19 pandemic: implications on interventional pain practice: a narrative review. Pain Physician. 2020; 23(4S): S311–18.Gharaei H., Diwan S. COVID-19 pandemic: implications on interventional pain practice: a narrative review. Pain Physician. 2020; 23(4S): S311–18.Long Q.X., Tang X.J., Shi Q.L., Li Q. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 2020; 26(8): 1200–4. DOI: 10.1038/s41591-020-0965-6Long Q.X., Tang X.J., Shi Q.L., Li Q. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 2020; 26(8): 1200–4. DOI: 10.1038/s41591-020-0965-6Nalbandian A., Sehgal K., Gupta A., Madhavan M.V. et al. Post-acute COVID-19 syndrome. Nat. Med. 2021; 27(4): 601–15. DOI: 10.1038/s41591-021-01283-zNalbandian A., Sehgal K., Gupta A., Madhavan M.V. et al. Post-acute COVID-19 syndrome. Nat. Med. 2021; 27(4): 601–15. DOI: 10.1038/s41591-021-01283-zTaquet M., Dercon Q., Luciano S., Geddes J.R. et al. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021; 18(9): e1003773. DOI: 10.1371/journal.pmed.1003773Taquet M., Dercon Q., Luciano S., Geddes J.R. et al. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021; 18(9): e1003773. DOI: 10.1371/journal.pmed.1003773Bileviciute-Ljungar I., Norrefalk J.R., Borg K. Pain burden in postCOVID-19 syndrome following mild COVID-19 infection. J. Clin. Med. 2022; 11(3): 771. DOI: 10.3390/jcm11030771Bileviciute-Ljungar I., Norrefalk J.R., Borg K. Pain burden in postCOVID-19 syndrome following mild COVID-19 infection. J. Clin. Med. 2022; 11(3): 771. DOI: 10.3390/jcm11030771Ali M., Bonna A.S., Sarkar A.S., Islam M.A. et al. SARS-CoV-2 infection is associated with low back pain: findings from a community-based case-control study. Int. J. Infect. Dis. 2022; 122: 144–51. DOI: 10.1016/j.ijid.2022.05.050Ali M., Bonna A.S., Sarkar A.S., Islam M.A. et al. SARS-CoV-2 infection is associated with low back pain: findings from a community-based case-control study. Int. J. Infect. Dis. 2022; 122: 144–51. DOI: 10.1016/j.ijid.2022.05.050Ali M., Ahsan G.U., Hossain A. Prevalence and associated occupational factors of low back pain among the bank employees in Dhaka City. J. Occup. Health. 2020; 62(1): e12131. DOI: 10.1002/1348-9585.12131Ali M., Ahsan G.U., Hossain A. Prevalence and associated occupational factors of low back pain among the bank employees in Dhaka City. J. Occup. Health. 2020; 62(1): e12131. DOI: 10.1002/1348-9585.12131Hartvigsen J., Hancock M.J., Kongsted A., Louw Q. et al. What low back pain is and why we need to pay attention. Lancet. 2018; 391(10137): 2356–67. DOI: 10.1016/S0140-6736(18)30480-XHartvigsen J., Hancock M.J., Kongsted A., Louw Q. et al. What low back pain is and why we need to pay attention. Lancet. 2018; 391(10137): 2356–67. DOI: 10.1016/S0140-6736(18)30480-XFatoye F., Gebrye T., Odeyemi I. Real-world incidence and prevalence of low back pain using routinely collected data. Rheumatol. Int. 2019; 39(4): 619–26. DOI: 10.1007/s00296-019-04273-0Fatoye F., Gebrye T., Odeyemi I. Real-world incidence and prevalence of low back pain using routinely collected data. Rheumatol. Int. 2019; 39(4): 619–26. DOI: 10.1007/s00296-019-04273-0Fiala K., Martens J., Abd-Elsayed A. Post-COVID pain syndromes. Curr. Pain Headache Rep. 2022; 26(5): 379–83. DOI: 10.1007/s11916-022-01038-6Fiala K., Martens J., Abd-Elsayed A. Post-COVID pain syndromes. Curr. Pain Headache Rep. 2022; 26(5): 379–83. DOI: 10.1007/s11916-022-01038-6Mokhtari T., Hassani F., Ghaffari N., Ebrahimi B. et al. COVID-19 and multiorgan failure: a narrative review on potential mechanisms. J. Mol. Histol. 2020; 51(6): 613–28. DOI: 10.1007/s10735-020-09915-3Mokhtari T., Hassani F., Ghaffari N., Ebrahimi B. et al. COVID-19 and multiorgan failure: a narrative review on potential mechanisms. J. Mol. Histol. 2020; 51(6): 613–28. DOI: 10.1007/s10735-020-09915-3Peiris S., Mesa H., Aysola A., Manivel J. et al. Pathological findings in organs and tissues of patients with COVID-19: a systematic review. PLoS One. 2021; 16(4): e0250708. DOI: 10.1371/journal.pone.0250708Peiris S., Mesa H., Aysola A., Manivel J. et al. Pathological findings in organs and tissues of patients with COVID-19: a systematic review. PLoS One. 2021; 16(4): e0250708. DOI: 10.1371/journal.pone.0250708Schiltenwolf M., Akbar M., Neubauer E., Gantz S. et al. The cognitive impact of chronic low back pain: positive effect of multidisciplinary pain therapy. Scand. J. Pain. 2017; 17: 273–8. DOI: 10.1016/j.sjpain.2017.07.019Schiltenwolf M., Akbar M., Neubauer E., Gantz S. et al. The cognitive impact of chronic low back pain: positive effect of multidisciplinary pain therapy. Scand. J. Pain. 2017; 17: 273–8. DOI: 10.1016/j.sjpain.2017.07.019Robertson D., Kumbhare D., Nolet P., Srbely J. et al. Associations between low back pain and depression and somatization in a Canadian emerging adult population. J. Can. Chiropr. Assoc. 2017; 61(2): 96–105.Robertson D., Kumbhare D., Nolet P., Srbely J. et al. Associations between low back pain and depression and somatization in a Canadian emerging adult population. J. Can. Chiropr. Assoc. 2017; 61(2): 96–105.Головачёва В.А., Парфёнов В.А. Лечение скелетно-мышечных болей в период пандемии COVID-19. Клиническая фармакология и терапия. 2022; 31(1): 24–31. DOI: 10.32756/0869-5490-2022-1-24-31Golovacheva V.A., Parfenov V.A. Treatment of musculoskeletal pain during COVID-19 pandemics. Clinical Pharmacology and Therapy. 2022; 31(1): 24–31 (in Russian). DOI: 10.32756/0869-5490-2022-1-24-31Камчатнов П.Р., Евзельман М.А., Чугунов А.В. Поражение периферической нервной системы при COVID-19. Русский медицинский журнал. 2021; 5: 30–4.Kamchatnov P.R., Evzelman M.A., Chugunov A.V. Peripheral nervous system disorders in COVID-19. Russian Medical Journal. 2021; 5: 30–4. (in Russian)Robb C., Goepp M., Rossi A., Yao C. Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. Br. J. Pharmacol. 2020; 177(21): 4899–920. DOI: 10.1111/bph.15206Robb C., Goepp M., Rossi A., Yao C. Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. Br. J. Pharmacol. 2020; 177(21): 4899–920. DOI: 10.1111/bph.15206Reese J.T., Coleman B., Chan L., Blau H. et al. NSAID use and clinical outcomes in COVID-19 patients: a 38-center retrospective cohortstudy. Virol. J. 2022; 19(1): 84. DOI: 10.1186/s12985-022-01813-2Reese J.T., Coleman B., Chan L., Blau H. et al. NSAID use and clinical outcomes in COVID-19 patients: a 38-center retrospective cohortstudy. Virol. J. 2022; 19(1): 84. DOI: 10.1186/s12985-022-01813-2Wong A.Y., MacKenna B., Morton C.E., Schultze A. et al. Use of nonsteroidal anti-infammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Ann. Rheum. Dis. 2021; 80(7): 943–51. DOI: 10.1136/annrheumdis-2020-219517Wong A.Y., MacKenna B., Morton C.E., Schultze A. et al. Use of nonsteroidal anti-infammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Ann. Rheum. Dis. 2021; 80(7): 943–51. DOI: 10.1136/annrheumdis-2020-219517Scalise M., Indiveri C. Repurposing nimesulide, a potent inhibitor of the B0AT1 subunit of the SARS-CoV-2 receptor, as a therapeutic adjuvant of COVID-19. SLAS Discov. 2020; 25(10): 1171–3. DOI: 10.1177/2472555220934421Scalise M., Indiveri C. Repurposing nimesulide, a potent inhibitor of the B0AT1 subunit of the SARS-CoV-2 receptor, as a therapeutic adjuvant of COVID-19. SLAS Discov. 2020; 25(10): 1171–3. DOI: 10.1177/2472555220934421Cava C., Bertoli G., Castiglioni I. In silico discovery of candidate drugs against Covid-19. Viruses. 2020; 12(4): 404. DOI: 10.3390/v12040404Cava C., Bertoli G., Castiglioni I. In silico discovery of candidate drugs against Covid-19. Viruses. 2020; 12(4): 404. DOI: 10.3390/v12040404Caiazzo E., Ialenti A., Cicala C. The relatively selective cyclooxygenase-2 inhibitor nimesulide: what's going on? Eur. J. Pharmacol. 2019; 848: 105–11. DOI: 10.1016/j.ejphar.2019.01.044Caiazzo E., Ialenti A., Cicala C. The relatively selective cyclooxygenase-2 inhibitor nimesulide: what's going on? Eur. J. Pharmacol. 2019; 848: 105–11. DOI: 10.1016/j.ejphar.2019.01.044Yang Z., Ji W., Li M., Qi Z. et al. Protective effect of nimesulide on acute lung injury in mice with severe acute pancreatitis. Am. J. Transl. Res. 2019; 11(9): 6024–31.Yang Z., Ji W., Li M., Qi Z. et al. Protective effect of nimesulide on acute lung injury in mice with severe acute pancreatitis. Am. J. Transl. Res. 2019; 11(9): 6024–31.Turkler C., Onat T., Yildirim E., Kaplan S. et al. Can the negative effects of ketamine abuse on female genital organs be prevented by nimesulide? An experimental study. Gen. Physiol. Biophys. 2019; 38(5): 427–34. DOI: 10.4149/gpb_2019023Turkler C., Onat T., Yildirim E., Kaplan S. et al. Can the negative effects of ketamine abuse on female genital organs be prevented by nimesulide? An experimental study. Gen. Physiol. Biophys. 2019; 38(5): 427–34. DOI: 10.4149/gpb_2019023Roberto G., Bartolini C., Rea F., Onder G. et al. Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE). NSAIDs utilization for musculoskeletal indications in elderly patients with cerebro/cardiovascular disease. Eur. J. Clin. Pharmacol. 2018; 74(5): 637–43. DOI: 10.1007/s00228-018-2411-yRoberto G., Bartolini C., Rea F., Onder G. et al. Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE). NSAIDs utilization for musculoskeletal indications in elderly patients with cerebro/cardiovascular disease. Eur. J. Clin. Pharmacol. 2018; 74(5): 637–43. DOI: 10.1007/s00228-018-2411-yPohjolainen T., Jekunen A., Autio L., Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine. 2000; 25(12): 1579–85. DOI: 10.1097/00007632-200006150-00019Pohjolainen T., Jekunen A., Autio L., Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine. 2000; 25(12): 1579–85. DOI: 10.1097/00007632-200006150-00019Шихкеримов Р.К. Применение нимесулида у пациентов с поясничной болью. Журнал неврологи и психиатрии им. С.С. Корсакова. 2016; 116(5): 28–32. DOI 10.17116/jnevro20161165128-32Shikhkerimov R.K. The use of nimesulide in the treatment of acute low back pain. S.S. Korsakov Journal of Neurology and Psychiatry. 2016; 116(5): 28–32. (in Russian). DOI 10.17116/jnevro20161165128-32Камчатнов П.Р., Казаков А.Ю., Чугунов А.В. Эффективность и безопасность применения нимесулида для лечения пациентов с дорсопатией. Consilium Medicum. 2016; 18(9): 116–21. DOI: 10.26442/2075-1753_2016.9.116-121Kamchatnov P.R., Kazakov A.Yu., Chugunov A.V. Efficacy and safety of nimesulide for the treatment of patients with dorsopathy. Consilium Medicum. 2016; 18(9): 116–21. (in Russian). DOI: 10.26442/2075-1753_2016.9.116-121Zhou L., Pang X., Jiang J., Zhong D. et al. Nimesulide and 4'-hydroxynimesulide as bile acid transporters inhibitors are contributory factors for drug-induced cholestasis. Drug Metab. Dispos. 2017; 45(5): 441–8. DOI: 10.1124/dmd.116.074104Zhou L., Pang X., Jiang J., Zhong D. et al. Nimesulide and 4'-hydroxynimesulide as bile acid transporters inhibitors are contributory factors for drug-induced cholestasis. Drug Metab. Dispos. 2017; 45(5): 441–8. DOI: 10.1124/dmd.116.074104Kwon J., Kim S., Yoo H., Lee E. Nimesulide-induced hepatotoxicity: a systematic review and meta-analysis. PLoS One. 2019; 14(1): e0209264. DOI: 10.1371/journal.pone.0209264Kwon J., Kim S., Yoo H., Lee E. Nimesulide-induced hepatotoxicity: a systematic review and meta-analysis. PLoS One. 2019; 14(1): e0209264. DOI: 10.1371/journal.pone.0209264Low E.X.S., Zheng Q., Chan E., Lim S.G. Drug induced liver injury: East versus West — a systematic review and meta-analysis. Clin. Mol. Hepatol. 2020; 26(2): 142–54. DOI: 10.3350/cmh.2019.1003Low E.X.S., Zheng Q., Chan E., Lim S.G. Drug induced liver injury: East versus West — a systematic review and meta-analysis. Clin. Mol. Hepatol. 2020; 26(2): 142–54. DOI: 10.3350/cmh.2019.1003Venegoni M., Da Cas R., Menniti-Ippolito F., Traversa G. et al. Effects of the European restrictive actions concerning nimesulide prescription: a simulation study on hepatopathies and gastrointestinal bleedings in Italy. Ann. Ist. Super Sanita. 2010; 46(2): 153–7. DOI: 10.4415/ANN_10_02_08Venegoni M., Da Cas R., Menniti-Ippolito F., Traversa G. et al. Effects of the European restrictive actions concerning nimesulide prescription: a simulation study on hepatopathies and gastrointestinal bleedings in Italy. Ann. Ist. Super Sanita. 2010; 46(2): 153–7. DOI: 10.4415/ANN_10_02_08Süleyman H., Demircan B., Karagöz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol. Rep. 2007; 59(3): 247–58.Süleyman H., Demircan B., Karagöz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol. Rep. 2007; 59(3): 247–58.Koizumi S., Odashima M., Otaka M., Jin M. et al. Attenuation of gastric mucosal inflammation induced by indomethacin through activation of the A2A adenosine receptor in rats. J. Gastroenterol. 2009; 44(5): 419–25. DOI: 10.1007/s00535-009-0028-8Koizumi S., Odashima M., Otaka M., Jin M. et al. Attenuation of gastric mucosal inflammation induced by indomethacin through activation of the A2A adenosine receptor in rats. J. Gastroenterol. 2009; 44(5): 419–25. DOI: 10.1007/s00535-009-0028-8Zak M.Y., Klymenko M.O., Iakovenko N.O., Grischenko G.V. Medicosocial value of osteoarthritis. secondary prevention and treatment of osteoarthritis in comorbidity with chronic gastritis. Wiad. Lek. 2019; 72(5 cz 2): 1064–7.Zak M.Y., Klymenko M.O., Iakovenko N.O., Grischenko G.V. Medicosocial value of osteoarthritis. secondary prevention and treatment of osteoarthritis in comorbidity with chronic gastritis. Wiad. Lek. 2019; 72(5 cz 2): 1064–7.Castellsague J., Riera-Guardia N., Calingaert B., Varas-Lorenzo C. et al. Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012; 35(12): 1127–46. DOI: 10.2165/11633470-000000000-00000Castellsague J., Riera-Guardia N., Calingaert B., Varas-Lorenzo C. et al. Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012; 35(12): 1127–46. DOI: 10.2165/11633470-000000000-00000Алексеева Л.И., Каратеев А.Е., Попкова Т.В., Новикова Д.С. и др. Эффективность и безопасность длительного применения нимесулида у больных остеоартрозом: результаты 12-месячного открытого контролируемого исследования ДИНАМО (Длительное Использование нимесулида при Артрозе Многофакторная Оценка). Научно-практическая ревматология. 2009; 4: 64–72.[Alekseeva L.I., Karateev A.E., Popkova T.V., Novikova D.S. et al. Efficacy and safety of nimesulide long term administration in patients with osteoarthritis: results of 12-months open controlled study DINAMO (long term administration of nimesulide in osteoarthritis multifactor assessment). Rheumatology Science and Practice. 2009; 4: 64–72. (in Russian)Scheinberg M., Pott H. Jr, de Almeida Macêdo E., Bocchi de Oliveira M.F. et al. Efficacy and safety of a fixed-dose combination of nimesulide/pantoprazole compared to naproxen/esomeprazole for pain relief in patients with osteoarticular diseases and dyspeptic symptoms. Drug Des. Devel. Ther. 2018; 12: 2775–83. DOI: 10.2147/DDDT.S172068Scheinberg M., Pott H. Jr, de Almeida Macêdo E., Bocchi de Oliveira M.F. et al. Efficacy and safety of a fixed-dose combination of nimesulide/pantoprazole compared to naproxen/esomeprazole for pain relief in patients with osteoarticular diseases and dyspeptic symptoms. Drug Des. Devel. Ther. 2018; 12: 2775–83. DOI: 10.2147/DDDT.S172068Fanelli A., Ghisi D., Aprile P.L., Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther. Adv. Drug Saf. 2017; 8: 173–82. DOI: 10.1177/2042098617690485Fanelli A., Ghisi D., Aprile P.L., Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther. Adv. Drug Saf. 2017; 8: 173–82. DOI: 10.1177/2042098617690485Masclee G.M.C., Straatman H., Arfè A., Castellsague J. et al. Risk of acute myocardial infarction during use of individual NSAIDs: a nested case-control study from the SOS project. PLoS One. 2018; 13(11): e0204746. DOI: 10.1371/journal.pone.0204746Masclee G.M.C., Straatman H., Arfè A., Castellsague J. et al. Risk of acute myocardial infarction during use of individual NSAIDs: a nested case-control study from the SOS project. PLoS One. 2018; 13(11): e0204746. DOI: 10.1371/journal.pone.0204746Schink T., Kollhorst B., Varas Lorenzo C., Arfè A. et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: a multi-country European database study within the SOS Project. PLoS One. 2018; 13(9): e0203362. DOI: 10.1371/journal.pone.0203362Schink T., Kollhorst B., Varas Lorenzo C., Arfè A. et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: a multi-country European database study within the SOS Project. PLoS One. 2018; 13(9): e0203362. DOI: 10.1371/journal.pone.0203362Rainsford K.D. Current status of the therapeutic uses and actions of the preferential cyclo-oxygenase-2 NSAID, nimesulide. Inflammopharmacology. 2006; 14(3–4): 120–37. DOI: 10.1007/s10787-006-1505-9Rainsford K.D. Current status of the therapeutic uses and actions of the preferential cyclo-oxygenase-2 NSAID, nimesulide. Inflammopharmacology. 2006; 14(3–4): 120–37. DOI: 10.1007/s10787-006-1505-9Singla A.K., Chawla M., Singh A. Nimesulide: some pharmaceutical and pharmacological aspects-an update. J. Pharm. Pharmacol. 2000; 52(5): 467–86. DOI: 10.1211/0022357001774255Singla A.K., Chawla M., Singh A. Nimesulide: some pharmaceutical and pharmacological aspects-an update. J. Pharm. Pharmacol. 2000; 52(5): 467–86. DOI: 10.1211/0022357001774255

The authors declare that there are no conflicts of interest present.